CClinicalTrials.gg
CompletedNCT06535217Updated Aug 2, 2024

Explainable Machine Learning for the Assessment of Donor Grafts in Liver Transplantation

An observational study in Liver Transplant; Complications, sponsored by Third Affiliated Hospital, Sun Yat-Sen University. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-02.

Sponsored by Third Affiliated Hospital, Sun Yat-Sen University · Observational

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
5,636
Ages
18 Years and older
Sex
All
01

Study summary

Clinically, organ evaluation generally performed by the senior surgeons based on their experience and the visual and tactual inspection of the graft during procurement. However, it is proved that transplant surgeons intuition in the evaluation of donor risk and the estimation of steatosis is inconsistent and usually inaccurate. Besides, graft assessment is a dynamic process refer to amount of complex factors, which is considered to be an incredibly complicated relationship that is nonlinear in nature. Unfortunately, the classical statistic techniques in vogue such as multiple regression require the statistical assumption of independent and linear relationships between explanatory and outcome variables, and fail to analyse a large number of variables. We attempted to develop liver graft assessment models by predicting postoperative DGF using several ML techniques. Secondly, the best prediction model was selected by comparing the performance of different AI algorithms and logistic regression. Finally, we sought to explain the decision made by AI algorithms using a visualization algorithm based on the best prediction model, helping clinicians evaluate specific organ and whether to receive that may develop DGF postoperatively.

02

Conditions studied

  • Liver Transplant; Complications
03

In context

Lead sponsor

Third Affiliated Hospital, Sun Yat-Sen University is the lead sponsor of 130 studies on the registry; 34 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients who underwent deceased donor liver transplantation

Inclusion criteria

  1. Age≥18 years-old
  2. Underwent deceased donor liver transplantation

Exclusion criteria

Exclusion Criteria:

  1. Underwent living-donor LT;
  2. Missing rates of data were more than 80%
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
5,636 participants (actual)
Patient registry
No

Groups and cohorts

  • DGF

    patients occured delayed graft function after liver transplantation

    Procedure: Liver transplantation

  • non-DGF

    patients NOT occured delayed graft function after liver transplantation

    Procedure: Liver transplantation

Interventions

  • ProcedureLiver transplantation

    Liver transplantation

06

What researchers measure

Primary outcomes

  1. Delayed Graft Function (DGF)

    defined as early graft dysfunction without the need for a second liver transplant or death

    Time frame: Within 7 days after liver transplantation

07

Study locations

1 site
  • The Third Affiliated Hospital of Sun Yat-Sen University
    Guangzhou, Guangdong, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 2, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06535217
Lead sponsor
Third Affiliated Hospital, Sun Yat-Sen University
Collaborators
the China Liver Transplant Registry
Responsible party
Zhixing Liang (M.D., Third Affiliated Hospital, Sun Yat-Sen University) — Principal investigator
First posted
Aug 2, 2024
Start date
Jan 1, 2017
Primary completion
Jun 30, 2023
Completion
Jun 30, 2024
Last update
Aug 2, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion